Wellbutrin XL Findings Could Cause FDA to Rethink Generic Drugs
A generic version of Wellbutrin XL recently had its brand equivalency designation removed by the Food and Drug Administration because of tests which suggested the active drug ingredient in these items wasn’t released at a rate equal to that of the brand drug. Patients reportedly filed complaints for years in regards to the generic before the FDA acted. Now, regulators are apparently rethinking testing procedures for these types of generics. Because generics are fairly cheap when compared to brand name drugs, they have become increasingly common. However, critics contend that there could be times when the generics are not as effective, as demonstrated in this instance.
For more information, click here.